Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Operating Leases (2019 - 2025)

Arrowhead Pharmaceuticals' Operating Leases history spans 7 years, with the latest figure at $109.7 million for Q4 2025.

  • For Q4 2025, Operating Leases changed 0.33% year-over-year to $109.7 million; the TTM value through Dec 2025 reached $109.7 million, changed 0.33%, while the annual FY2025 figure was $104.1 million, 6.23% down from the prior year.
  • Operating Leases reached $109.7 million in Q4 2025 per ARWR's latest filing, up from $104.1 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $115.2 million in Q4 2023 to a low of $22.5 million in Q4 2021.
  • Average Operating Leases over 5 years is $80.9 million, with a median of $93.4 million recorded in 2023.
  • Peak YoY movement for Operating Leases: surged 265.22% in 2022, then fell 6.23% in 2025.
  • A 5-year view of Operating Leases shows it stood at $22.5 million in 2021, then soared by 265.22% to $82.1 million in 2022, then skyrocketed by 40.21% to $115.2 million in 2023, then fell by 5.09% to $109.3 million in 2024, then grew by 0.33% to $109.7 million in 2025.
  • Per Business Quant, the three most recent readings for ARWR's Operating Leases are $109.7 million (Q4 2025), $104.1 million (Q3 2025), and $105.7 million (Q2 2025).